Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran.
Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, VIC 3168, Australia.
Nutrients. 2022 Aug 6;14(15):3224. doi: 10.3390/nu14153224.
Cardiovascular disease (CVD) is the leading cause of death in patients with non-alcoholic fatty liver disease (NAFLD). Curcumin has been shown to exert glucose-lowering and anti-atherosclerotic effects in type 2 diabetes. Hence, we investigated curcumin's effects on atherogenesis markers, fatty liver, insulin resistance, and adipose tissue-related indicators in patients with NAFLD. In this secondary analysis of a 12-week randomized controlled trial, fifty-two patients with NAFLD received lifestyle modification. In addition, they were randomly allocated to either the curcumin group (1.5 g/day) or the matching placebo. Outcome variables (assessed before and after the study) were: the fatty liver index (FLI), hepatic steatosis index (HSI), fatty liver score (FLS), BMI, age, ALT, TG score (BAAT), triglyceride glucose (TyG) index, Castelli risk index-I (CRI-I), Castelli risk index-II (CRI-II), TG/HDL-C ratio, atherogenic coefficient (AC), atherogenic index of plasma (AIP), lipoprotein combine index (LCI), cholesterol index (CHOLINDEX), lipid accumulation product (LAP), body adiposity index (BAI), visceral adiposity index (VAI), metabolic score for visceral fat (METS-VF), visceral adipose tissue (VAT), and waist-to-height ratio (WHtR) values. The TyG index decreased in the curcumin group and increased in the placebo group, with a significant difference between the groups ( = 0.029). However, a between-group change was not significant after adjustment for multiple testing. Other indices were not significantly different between the groups either before or after multiple test correction. After the intervention, there was a lower number of patients with severe fatty liver (FLI ≥ 60) and metabolic syndrome in the curcumin group compared to the placebo ( = 0.021 and = 0.012, respectively). In conclusion, curcumin offers no additional cardiometabolic benefits to lifestyle intervention in patients with NAFLD.
心血管疾病（CVD）是非酒精性脂肪肝（NAFLD）患者死亡的主要原因。姜黄素已被证明在 2 型糖尿病中具有降血糖和抗动脉粥样硬化作用。因此，我们研究了姜黄素对 NAFLD 患者动脉粥样硬化标志物、脂肪肝、胰岛素抵抗和脂肪组织相关指标的影响。在这项为期 12 周的随机对照试验的二次分析中，52 名 NAFLD 患者接受了生活方式改变。此外，他们被随机分配到姜黄素组（每天 1.5 克）或匹配的安慰剂组。研究前后评估的结局变量为：脂肪肝指数（FLI）、肝脂肪变性指数（HSI）、脂肪肝评分（FLS）、BMI、年龄、ALT、三酰甘油葡萄糖（TyG）指数、甘油三酯高密度脂蛋白胆固醇比值（TG/HDL-C 比值）、卡斯特利风险指数-I（CRI-I）、卡斯特利风险指数-II（CRI-II）、载脂蛋白组合指数（LCI）、胆固醇指数（CHOLINDEX）、脂蛋白结合指数（LPI）、脂类蓄积产物（LAP）、身体肥胖指数（BAI）、内脏脂肪指数（VAI）、内脏脂肪代谢评分（METS-VF）、内脏脂肪组织（VAT）和腰高比（WHtR）值。姜黄素组的 TyG 指数下降，安慰剂组的 TyG 指数上升，两组间有显著差异（ = 0.029）。然而，在经过多次测试校正后，组间差异无统计学意义。其他指标在多次测试校正前后两组间也无显著差异。干预后，姜黄素组中脂肪肝严重程度（FLI≥60）和代谢综合征患者数量低于安慰剂组（分别为 = 0.021 和 = 0.012）。总之，姜黄素对 NAFLD 患者的生活方式干预没有额外的代谢益处。
